United States-based Pfizer is opening a new manufacturing facility in Andover, Massachusetts, it was reported yesterday.
The facility covers a 175,000 square-foot area. It accommodates commercial manufacturing and product development functions for the development and production of complex biologics and vaccines. The site will offer 75 new jobs for the Andover area economy, adding to the around 2,000 staff currently based in Massachusetts.
The newly opened Andover Clinical Manufacturing Facility will expand the capacity for Pfizer's BioTherapeutics Pharmaceutical Sciences organization to manufacture clinical supplies. The company's ACMF investment is more than USD200m and includes five independent manufacturing suites, with more than 50 projects currently in development.
Merck launches Phase 3 trial for dengue vaccine candidate V181
BioNet and Bio Farma sign MoU on TdaP vaccine
Dx&Vx accelerates universal COVID-19 vaccine development
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
CTP delivers 18,000 sqm Serbian facility for SCHOTT Pharma to support global expansion
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Orexo reports positive results for powder-based intranasal vaccine using AmorphOX technology
GC Biopharma's BARYTHRAX receives Korean regulatory approval
GSK grants USD2m to boost adult vaccination efforts
Valneva and LimmaTech begin Phase 2 infant trial for Shigella vaccine candidate S4V2
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100